Immuneering Co. (NASDAQ:IMRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immuneering Co. (NASDAQ:IMRX) have earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.60.

Several research firms recently commented on IMRX. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Immuneering in a research note on Thursday, November 14th. Chardan Capital reduced their price objective on shares of Immuneering from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th.

Immuneering Trading Up 13.3 %

Shares of Immuneering stock opened at $2.04 on Wednesday. The business has a 50-day moving average price of $2.19 and a two-hundred day moving average price of $1.62. Immuneering has a 1-year low of $1.00 and a 1-year high of $8.89. The company has a market cap of $63.34 million, a P/E ratio of -1.04 and a beta of -0.40.

Institutional Trading of Immuneering

Hedge funds and other institutional investors have recently bought and sold shares of the business. Corsair Capital Management L.P. bought a new position in shares of Immuneering in the third quarter valued at $25,000. Vontobel Holding Ltd. acquired a new stake in shares of Immuneering in the 3rd quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Immuneering in the 2nd quarter valued at about $44,000. XTX Topco Ltd boosted its stake in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Immuneering during the 2nd quarter worth approximately $67,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.